23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
21:36 , May 30, 2018 |  BC Extra  |  Preclinical News

Tet2 disruption improves Kymriah efficacy

In a Nature study, researchers at the University of Pennsylvania identified a patient with an enhanced response to CAR T therapy Kymriah tisagenlecleucel, and suggested targeting the epigenome by inhibiting Tet2 could improve the efficacy...
19:06 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting CHI3L1 could help treat lung metastases of melanoma. In mouse melanoma cells co-cultured with mouse CD8+ T cells, CHI3L1 knockout in the T cells increased cytotoxic T...
23:39 , Oct 27, 2017 |  BC Extra  |  Preclinical News

Cell study points to new antibiotic strategy

A study in Cell shows granzyme B (GrB; GZMB), an immune cell protease, kills diverse bacterial species by shutting down multiple conserved survival pathways. The authors suggest compounds that mimic the protease’s mechanism could treat...
18:41 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG-positive cervical and breast cancers. In cervical cancer patient samples,...
08:00 , Feb 18, 2016 |  BC Innovations  |  Targets & Mechanisms

Staking out foxholes

A pair of studies from a Memorial Sloan Kettering Cancer Center (MSKCC) lab has uncovered two new handles for tuning the immune system to fight solid tumors. By focusing on processes that regulate immune suppression...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

viDA Therapeutics, Centre for Drug Research and Development deal

The center and viDA partnered to develop VTI-1002 to treat discoid lupus erythematosus (DLE). The partners will develop a clinical-grade formulation of the preclinical topical small molecule granzyme B (GrB; GZMB) inhibitor...
07:00 , Oct 29, 2015 |  BC Innovations  |  Translation in Brief

Tumor turncoat

Instead of engineering T cells to kill tumors, researchers at The Scripps Research Institute have found a way to direct a patient's own leukemia cells to kill each other by using an agonist antibody that...
07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Bone marrow transplant (BMT) Granzyme B (GrB; GZMB) Mouse studies suggest inhibiting GZMB could help improve bone...
08:00 , Feb 13, 2014 |  BC Innovations  |  Tools & Techniques

Micromanaging the microenvironment

A Massachusetts team has designed an in vivo shRNA screen to discover immunosuppressive tumor targets that can be blocked to improve the efficacy of T cell immunotherapies.1 The screening system shows that current checkpoint inhibitors...